Care Ratings is only for the patient investor, its has a long runway for the simple reason that Credit Cycle is not currently playing out, and when its starts, CARE being one of the 3 beneficiaries in the rating space will be at an advantage. The company also has some subsidiaries, which have potential to throw up some surprises. one such subsidiary is “Care Edge Analytics” it has great scope for growth.
Just check for Moody’s Analytics has grown, and it is a global leader in its space.
https://www.moodys.com/web/en/us/insights/announcements/moodysanalytics-is-now-moodys.html
check out their products.
Every drop in the stock is a great chance to add.
Subscribe To Our Free Newsletter |